Market Analysis: Hypertension, Cystic Fibrosis, Rheumatoid Drugs

This report provides a market analysis of drugs used to treat hypertension, cystic fibrosis, and rheumatoid arthritis. It examines the market dynamics of Clonidine, a hypertension drug, noting its increasing sales volume and the rising prevalence of hypertension globally. The analysis also covers cystic fibrosis therapeutics, highlighting the increasing demand driven by a rise in patient numbers and R&D investments, and rheumatoid arthritis drugs, projecting market growth due to emerging biologics and an aging population. Key market players, therapy types, and geographical segmentation are discussed, emphasizing the importance of awareness creation and continuous drug development to maintain market share. Desklib offers similar solved assignments and past papers for students.

Running head:MARKET ANALYSIS ON DRUGS
1
1
Market analysis on drugs
Name
Institution
Professor
Course
Date

MARKET ANALYSIS ON DRUGS
2
Market analysis for hypertension drugs market (Clonidine)
Clonidine has become largely available for prescription as a hypersensitive drug and its
use has increased its sales volume in the global market this drug is highly convenient in patients
with both minimal and severe hypertension. In comparison with other drugs, this drug has
relatively low dosage per day. As a result of various factors such as high urbanization and
globalization, people are being adversely affected by a coronary disease, heart complications due
to high blood pressure. Across the world, it is estimated that 1.12 individuals suffer from
hypertension. Accounting for approximately brings 15 million deaths. High blood pressure
causes other diseases like heart failure and visual impairment which makes hypertension drugs to
have a high demand in the market especially clonidine drug that is used in this case for treatment.
The rise of people living lifestyle and increased stress levels has had a high prevalence of
hypertension globally which in turn results to rise in the demand curve of Clonidine hypertension
drug. The older people in the society are most likely to have a maximum risk of suffering high
blood pressure. Thus approximately 69% of the people with over 60 years of age suffer from
hypertension and hypertension-related diseases (Novac 2013). Therefore, a rise in the number
of old people receiving medical care regarding hypertension will boost the market growth and
development during the forecast period. In addition to that, the increase in awareness creation
programs and workshops among individuals in terms of instilling knowledge on hypertension
and its available clonidine treatment drug options will drive the growth of the global market
further. A patent expiration date of major drugs and decreased diagnostic rate and also rise in the
number of other available generic drugs could tamper with the market growth rate of Clonidine
drug..

MARKET ANALYSIS ON DRUGS
3
Various researches provides an extensive study on the analysis regarding the current and
new emerging market trends and dynamics in the existing global market. They detail a unitive
analysis of the current market estimations from a range of years which is significant in
identifying the prevailing market opportunities available. It projects the future anticipated
marketability from 2016-2022 regarding its amount value. It enables marketers to understand
clearly on the competitive sector across the global market. Also, an in-depth analysis has modern
research strategies involving clinical reports within the existing potential market have been
provided. The available dynamic factors aid the marketers to understand the behavior of the
market. The Clonidine incremental costs in the market value were 29.09USD and 75.
52$Us.During analyzed variations in the market prices of the drug which is cost effective.
Market Research carried out by analysts at Technavio has indicated that the global
hypertension drugs market will have an impressive market value of approximately USD 31
billion by the year 2020. The risk of contracting hypertension increases with age thus the
developing old people population will help in potential growth prospects of hypertension drug in
the market over given period of time (Siebenhofer et al 2013). Various industry reports discuss
factors for example awareness creation that impel the market increase prospects by the year
2020. In 2015 the systemic hypertension drugs like Clonidine segment dominated the drug
market focusing on alomst86& of the global market share. Its systemic market is anticipated to
reach over USD 27 in the coming years. During 2015 the Americas were accounted for the most
massive market for high blood pressure drugs accounting for over 43% market share. The global
market of these drugs is largely consolidated because of the availability of less clearly
established vendors. Companies are investing heavily in the growth of new drugs for the
treatment of hypertension patients. (Siebenhofer et al 2013).

MARKET ANALYSIS ON DRUGS
4
Cystic fibrosis therapeutics
The overall market size of cystic fibrosis therapeutics at international level was
approximated at the value of 3.56 billion US dollars in the year 2016. The rising preference of
this type of drug comprised of the increasing treatment rate at health facilities is one of the main
factors that lead to the expected drive for the high demand for this therapeutics over the
anticipated period. (O'Sullivan et al 2013). In addition, the increase in R&D amount of funds by
private and government organizations, high number of public initiatives that are started by
nonprofit enterprises and also the availability of maximum reimbursement policies and strategies
are some of the critical reasons required to propel the market forward. According to research data
published by drug foundation, the situations arising due to hereditary diseases is constantly
developing. In the U. S, the number of patients grew by approximately 1,600 in 2015 as
compared to the year 2010. The increasing growth of a number of patients leads to increased
demand for this drug in the market.
Fig 1.1 U.S cystic fibrosis therapeutics market
The rising number of drug components in the pipeline has played a key role in the main
factors leading to impel anticipated market growth. Also, the increasing number of clinical trials

MARKET ANALYSIS ON DRUGS
5
to widen its patient with disorders base with the existing drug market are one of the drivers of
this market analysis (O'Sullivan et al 2013). The presence of several non-profitable
organizations, for example, national Cystic Fibrosis foundation involved in the operations related
to CF is significant in accounting for the rising demand. They are investing massive amounts to
acquire distinct therapeutics for CF and market research analysis.
Based on the drug class the market is segmented into mucolytic and CFTR drug
modulators. These were launched as the only modulator drug in the market has high revenue
with a share of 47.3%.
Areas where demand for topical are high RetP system
Cystic fibrosis therapeutics drugs
Cystic fibrosis therapeutics drugs have high demand in topic Caucasian areas as it affects like
70000 affected patients worldwide.
The Regents engineering transfer programs is on high demand in universities where
science and engineering educations for studying the various drugs such as Cystic fibrosis
therapeutics. These key areas expand the knowledge on the global market demand of Cystic
fibrosis therapeutics drugs as it offers the research on their manufacture and supply to the global
market. They end up having high demand for example in countries such as Europewhich is
typically anticipated to be the second most key lucrative market with an attractive index of 1.1.
Rheumatoid Arthritis

MARKET ANALYSIS ON DRUGS
6
Its international market size is anticipated to reach USD 30.4 billion in the next 7 years as
indicated by Grand View research (Gupta et al 2017). Various emerging trends propelling this
market is the presence of biologics, rising prospective clinical trials and the increasing aged
individuals. The rising availability and awareness created by safe drugs are driven to surge the
market growth of rheumatoid arthritis drugs. The growing prevalence of this drug type and
availability of novel biosimilar provide high market share for the drug in the market leading to
increased health expenditure. New emerging products such as Infliximab biologics are expected
to favor the market demand for Rheumatoid Arthritis drug.
Hypertension drugs
The global Clonidine drug market is usually segmented based on the existing therapy
type and geography location/areas where the drug is needed most. In terms of the therapy type,
the market has various categories including beta blockers, alpha blockers, diuretics and renin
inhibitors among other more. In terms of geographic locations, the market is analyzed across
several countries such as North America, Europe, and the Pacific (Novac 2013). The key market
players of Clonidine drug include Ranbaxy Laboratories Limited, Pfizer Inc. and Lupine limited.
These market players provide a competitive market analysis and profiles of hypertension drugs.
These areas that has high prevalence for the drugs will benefit a lot from the increased
market demand. Many people are mostly getting affected by the disease especially the aged
people in the given areas. The created awareness is also enabling the drug manufacturing
companies to get high demand for the drugs in order to maintain continuous market supply
globally. In the market this will create large sales volume of the drugs which in turn is

MARKET ANALYSIS ON DRUGS
7
advantageous to the company’s profitability. The companies will use the The Regents
engineering transfer programs to identify and, modify and develop new drugs for the in order to
maintain the growing competition from other developing companies that manufacture similar
drugs and who will control the market share in the global sector. Thus these companies will
ensure emergence of new drugs in the market for treatment of the various diseases.

MARKET ANALYSIS ON DRUGS
8
References
Picavet, E., Annemans, L., Cleemput, I., Cassiman, D., & Simoens, S. (2012). Market uptake of
orphan drugs–a European analysis. Journal of clinical pharmacy and therapeutics, 37(6), 664-
667.
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., & Semlitsch, T. (2013). Long-term effects of
weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev, 3.
O'Sullivan, B. P., Orenstein, D. M., & Milla, C. E. (2013). Pricing for orphan drugs: will the
market bear what society cannot?. Jama, 310(13), 1343-1344.
Syed, B. A., & Chaudhari, K. (2013). Smoking cessation drugs market.
Li, W., Joshi, M. D., Singhania, S., Ramsey, K. H., & Murthy, A. K. (2014). Peptide vaccine:
progress and challenges. Vaccines, 2(3), 515-536.
Dougla, R. G., & Samant, V. B. (2012). The vaccine industry. Plotkin S, Orenstein Offit P, eds.
Vaccines. 6th ed. Saunders Elsevier, 33-43.
Andrieux-Meyer, I., Cohn, J., de Araújo, E. S. A., & Hamid, S. S. (2015). The disparity in
market prices for hepatitis C virus direct-acting drugs. The Lancet Global Health, 3(11), e676-
e677.
Novac, N. (2013). Challenges and opportunities of drug repositioning. Trends in pharmacological sciences, 34(5),
267-272.